Ascendis Pharma A/S (ASND) Projected to Post Quarterly Earnings on Thursday

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) is anticipated to release its Q1 2025 earnings data after the market closes on Thursday, May 1st. Analysts expect Ascendis Pharma A/S to post earnings of ($1.56) per share and revenue of $98.56 million for the quarter.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($1.32) by $0.64. On average, analysts expect Ascendis Pharma A/S to post $-4 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ascendis Pharma A/S Stock Up 1.0 %

ASND stock traded up $1.70 during trading on Tuesday, hitting $166.58. 276,857 shares of the company's stock traded hands, compared to its average volume of 488,984. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $169.37. The stock has a fifty day moving average price of $154.21 and a two-hundred day moving average price of $139.47. The stock has a market capitalization of $10.16 billion, a price-to-earnings ratio of -23.46 and a beta of 0.54.

Analyst Ratings Changes

Several research firms have weighed in on ASND. The Goldman Sachs Group boosted their target price on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. UBS Group started coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a "buy" rating and a $196.00 price target for the company. Morgan Stanley set a $180.00 price target on shares of Ascendis Pharma A/S in a research report on Tuesday, February 18th. Royal Bank of Canada started coverage on shares of Ascendis Pharma A/S in a research report on Wednesday, April 16th. They set an "outperform" rating and a $205.00 price target for the company. Finally, Cantor Fitzgerald upped their price target on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 25th. Two analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $204.67.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.